Stemline

STML NASDAQ
12.72
-0.49
-3.71%
Opening 14:39 07/15 EDT
Open
13.26
Prev Close
13.21
High
13.38
Low
12.54
Volume
363.98K
Avg Vol (3M)
496.58K
52 Week High
17.85
52 Week Low
7.82
% Turnover
0.83%
Market Cap
555.67M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Stemline STML stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
MORE >

Recently

Name
Price
%Change